News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
256,009 Results
Type
Article (6226)
Company Profile (31)
Press Release (249752)
Multimedia
Podcasts (2)
Webinars (5)
Section
Business (88515)
Career Advice (474)
Deals (16600)
Drug Delivery (10)
Drug Development (21735)
Employer Resources (33)
FDA (4099)
Job Trends (4644)
News (131213)
Policy (8501)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (384)
Accelerated approval (10)
Adcomms (4)
Allergies (15)
Alliances (16552)
ALS (45)
Alzheimer's disease (396)
Antibody-drug conjugate (ADC) (48)
Approvals (4212)
Artificial intelligence (101)
Autoimmune disease (34)
Automation (5)
Bankruptcy (107)
Best Places to Work (3477)
Biosimilars (32)
Biotechnology (32)
Bladder cancer (37)
Brain cancer (11)
Breast cancer (151)
Cancer (1085)
Cardiovascular disease (76)
Career advice (406)
Career pathing (4)
CAR-T (71)
CDC (2)
Cell therapy (186)
Cervical cancer (4)
Clinical research (18869)
Collaboration (413)
Compensation (377)
Complete response letters (8)
COVID-19 (472)
CRISPR (25)
C-suite (353)
Cystic fibrosis (32)
Data (1531)
Denatured (1)
Depression (25)
Diabetes (85)
Diagnostics (2469)
Digital health (7)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (50)
Drug pricing (14)
Drug shortages (2)
Duchenne muscular dystrophy (46)
Earnings (44914)
Editorial (5)
Employer branding (6)
Employer resources (34)
Events (42651)
Executive appointments (449)
FDA (4906)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (407)
Gene editing (40)
Generative AI (6)
Gene therapy (110)
GLP-1 (167)
Government (533)
Guidances (204)
Healthcare (5704)
HIV (10)
Huntington's disease (5)
IgA nephropathy (18)
Immunology and inflammation (42)
Immuno-oncology (8)
Indications (16)
Infectious disease (505)
Inflammatory bowel disease (37)
Inflation Reduction Act (3)
Influenza (6)
Intellectual property (37)
Interviews (57)
IPO (8538)
IRA (3)
Job creations (1266)
Job search strategy (367)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (113)
Leadership (5)
Legal (2685)
Liver cancer (21)
Longevity (5)
Lung cancer (115)
Lymphoma (77)
Machine learning (4)
Management (11)
Manufacturing (154)
MASH (50)
Medical device (4378)
Medtech (4390)
Mergers & acquisitions (8530)
Metabolic disorders (225)
Multiple sclerosis (23)
NASH (6)
Neurodegenerative disease (66)
Neuropsychiatric disorders (14)
Neuroscience (683)
NextGen: Class of 2026 (1824)
Non-profit (833)
Now hiring (5)
Obesity (89)
Opinion (36)
Ovarian cancer (27)
Pain (33)
Pancreatic cancer (53)
Parkinson's disease (52)
Partnered (12)
Patents (71)
Patient recruitment (108)
Peanut (6)
People (27412)
Pharmaceutical (11)
Pharmacy benefit managers (2)
Phase I (5659)
Phase II (8330)
Phase III (6463)
Pipeline (2026)
Policy (17)
Postmarket research (660)
Preclinical (2298)
Press Release (67)
Prostate cancer (70)
Psychedelics (5)
Radiopharmaceuticals (129)
Rare diseases (191)
Real estate (2040)
Recruiting (9)
Regulatory (6160)
Reports (18)
Research institute (405)
Resumes & cover letters (69)
Rett syndrome (19)
RNA editing (4)
RSV (2)
Schizophrenia (60)
Series A (59)
Series B (59)
Service/supplier (2)
Sickle cell disease (13)
Special edition (1)
Spinal muscular atrophy (33)
Sponsored (7)
Startups (1154)
State (1)
Stomach cancer (1)
Supply chain (17)
Tariffs (7)
The Weekly (1)
Vaccines (107)
Venture capital (10)
Weight loss (30)
Women's health (6)
Date
Today (25)
Last 7 days (134)
Last 30 days (732)
Last 365 days (10229)
2026 (732)
2025 (10305)
2024 (12487)
2023 (14822)
2022 (20770)
2021 (22146)
2020 (19965)
2019 (14528)
2018 (11184)
2017 (11073)
2016 (10211)
2015 (13402)
2014 (10518)
2013 (8470)
2012 (9181)
2011 (9561)
2010 (9335)
Location
Africa (203)
Alabama (18)
Alaska (2)
Arizona (84)
Arkansas (1)
Asia (12698)
Australia (1792)
California (3740)
Canada (1756)
China (179)
Colorado (152)
Connecticut (168)
Delaware (79)
Europe (27641)
Florida (575)
Georgia (74)
Idaho (24)
Illinois (179)
India (15)
Indiana (138)
Iowa (9)
Japan (178)
Kansas (37)
Kentucky (19)
Louisiana (8)
Maine (51)
Maryland (366)
Massachusetts (2970)
Michigan (142)
Minnesota (232)
Mississippi (1)
Missouri (31)
Montana (17)
Nebraska (14)
Nevada (55)
New Hampshire (27)
New Jersey (1242)
New Mexico (8)
New York (930)
North Carolina (527)
North Dakota (5)
Northern California (1952)
Ohio (116)
Oklahoma (8)
Oregon (6)
Pennsylvania (688)
Puerto Rico (2)
Rhode Island (19)
South America (313)
South Carolina (17)
Southern California (1354)
Tennessee (71)
Texas (561)
United States (13510)
Utah (115)
Virginia (85)
Washington D.C. (18)
Washington State (319)
West Virginia (2)
Wisconsin (68)
Wyoming (2)
256,009 Results for "zenith epigenetics corp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Zenith Epigenetics’ ZEN-3694 Receives Orphan Drug Designation from FDA
October 27, 2025
·
6 min read
Press Releases
FDA grants Zenith’s ZEN-3694 Fast Track Status
Zenith Epigenetics Announces Grant of U.S. Food and Drug Administration Fast Track Designation for ZEN-3694 in NUT Carcinoma
July 14, 2025
·
5 min read
Zenith Epigenetics Proudly Supports Rare Disease Day
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announces its support of Rare Disease Day by highlighting our expanded development efforts of BET inhibitor ZEN-3694
February 29, 2024
·
5 min read
Press Releases
Monaghan Medical Earns 2025 AARC Zenith Award — A Decade of Trust and Innovation Recognized by Respiratory Care Professionals
December 8, 2025
·
3 min read
Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694
Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a global leader in epigenetics, announced today it has entered into an agreement with Cencora (formerly AmerisourceBergen) aimed at accelerating the commercialization of Zenith Epigenetics’ ZEN-3694 program.
October 26, 2023
·
7 min read
Press Releases
Zenith Capital Corp. Provides Update on the Company’s Upcoming Annual General Meeting
December 16, 2024
·
5 min read
Press Releases
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
October 2, 2025
·
10 min read
Press Releases
Renew Biotechnologies Advances Epigenetic Diagnostics Through Launch of Path Fertility’s NOA Guide
January 30, 2026
·
2 min read
Press Releases
Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
September 24, 2024
·
3 min read
Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) reports clinical activity and the advancement in development of its BET inhibitor (BETi) ZEN-3694 in patients with NUT carcinoma (NC). NC is a highly aggressive type of squamous cell cancer with very poor prognosis that often forms in the head, neck, or lungs.
June 1, 2023
·
6 min read
1 of 25,601
Next
